Alternative options could improve cervical cancer screening rate among transgender men, study shows

A new study indicates that alternative options for cervical cancer screening, including self-sampling for human papilloma virus (HPV) testing, could improve the screening rate among transgender men. More than half of the participants expressed a preference for HPV self-sampling in the study published in LGBT Health, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the LGBT Health website until October 6, 2017.

Approximately half of the study participants did not have a Pap smear to screen for cervical cancer within the previous 3 years, according to coauthors Julia Seay, PhD, Roy Weiss, MD, Christopher Salgado, MD, Lydia Fein, MD, and Erin Kobetz, PhD, MPH, University of Miami, FL, and Atticus Ranck, Sunshine Social Services, Inc., Fort Lauderdale, FL. In the article entitled "Understanding Transgender Men's Experiences with and Preferences for Cervical Cancer Screening: A Rapid Assessment Survey," the authors emphasize the need for innovative primary screening alternatives such as HPV self-sampling and the importance of testing the effectiveness of this approach in transgender men in future studies.

"This important study identifies factors, including HPV self-sampling, that may improve cervical cancer screening among transgender men with a cervix and translate into reduced cervical cancer morbidity and mortality in this population," says LGBT Health Editor-in-Chief William Byne, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients